Hepatocellular carcinoma: Current treatment strategies

Current Treatment Options in Gastroenterology

Volumn 8, Issue 6, 2005, Pages 457-466

  Shields, Aaron ^a   Reddy, K Rajender ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ALCOHOL; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; HEPATITIS C VACCINE; INTERFERON; MITOMYCIN C; YTTRIUM 90;

CANCER DIAGNOSIS; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; CRYOTHERAPY; DRUG FATALITY; FEVER; GRAFT FAILURE; HEALTH CARE POLICY; HEMOPERITONEUM; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATIENT MONITORING; PLEURA EFFUSION; PREVALENCE; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; STRATEGIC PLANNING; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME; ULTRASOUND;

EID: 30344473604     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0032-x     Document Type: Review

References (60)

1. El-Serag HB, Davila JA, Petersen NJ, et al.: The continuing increase in the incidence of hepatocellular carcinoma in the United States. Ann Intern Med 2003, 139:817-832.
2. Parkin DM, Bray F, Ferlay J, et al.: Estimating the world cancer burden: Globocon 2000. Int J Cancer 2001, 94:153-156.
3. El-Serag HB: Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36:S74-S83.
4. Sangiovanni A, Del Ninno E, Fasani P, et al.: Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126:1005-1014.
5. Benvegnù L, Gios M, Boccato S, et al.: Natural history of compensated cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004, 53:744-749.
6. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
7. Marrero JA, Fontana RJ, Barrat A, et al.: Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41:707-716.
8. Burroughs A, Hochhauser D, Meyer T: Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet 2004, 5:409-418.
9. Carr BI: Hepatic arterial 90Yttrium glass microspheres (Theraspheres) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004, 10(2 Suppl 1):S107-S110.
10. Trevisani F, De NS, Rapaccini G, et al.: Semianual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002, 97:734-744.
11. Sherman M: Alpafetoprotein: An obituary. J Hepatol 2001, 34:603-605.
12. Bolondi L, Sofia S, Siringo S, et al.: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a costeffective analysis. Gut 2001, 48:251-259.
13. Bruix J, Sherman M, Llovet JM, et al.: Conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
14. Marrero JA, Hussain HK, Nghiem HV, et al.: Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005, 11:281-289.
15. Soresi M, Magliarisi C, Campagna P, et al.: Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003, 23:1747-1753.
16. Durand F, Regimbeau JM, Belghiti J, et al.: Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001, 35:254-258.
17. Regimbeau JM, Kianmanesh R, Farges O, et al.: Extent of liver resection influences the outcome in patients with cirrhosis and small HCC. Surgery 2002, 131:311-317.
18. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
19. Sun HC, Tang ZY: Preventative treatments for recurrence after curative resection of hepatocellular carcinoma. Rev Gastroenterol Disord 2003, 9:635-640.
20. Llovet JM, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
21. Tung-Ping PR, Fan ST, Wong J: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000, 232:10-24.
22. Llovet JM, Mas X, Aponte JJ, et al.: Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002, 50:123-128.
23. Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
24. Jonas S, Bechstein WO, Steinmuller I, et al.: Vascular invasion and histopathological grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33:1080-1086.
25. Yao FY, Ferrell L, Bass WM, et al.: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
26. Kulik L, Abecassis M: Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004, 127:S277-S282.
27. Freeman RB, Wiesner RH, Edwards E, et al.: Results of the first year of the new liver allocation plan. Liver Transpl 2004, 10:7-15.
28. Ryder SR: Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC). Gut 2003, 52 (Suppl 3): iii1-8.
29. Lo CM, Fan ST: Liver transplantation for hepatocellular carcinoma. Br J Surg 2004, 91:131-133.
30. Sarasin FP, Majno PE, Llovet JM, et al.: Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 2001, 33:1073-1079.
31. Pacella CM, Bizzarri G, Magnolfi F, et al.: Laser thermal ablation in the treatment of small hepatocellular carcinoma: results in 74 patients. Radiology 2001, 221:712-720.
32. Leyendecker JR, Dodd GD 3rd: Minimally invasive techniques for the treatment of liver tumors. Semin Liver Dis 2001, 21:283-291.
33. Dodd GD 3rd, Napier D, Schoolfield JD, et al.: Percutaneous radiofrequency ablation for hepatic tumors: postablation syndrome. AJR Am J Roentgenol 2005, 185:51-57.
34. Mulier S, Mulier P, Miao Y, et al.: Complications of radiofrequency coagulation of liver tumors. Br J Surg 2002, 89:1206-1222.
35. Curley SA, Izzo F, Ellis LM, et al.: Radiofrequency ablation in hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000, 232:381-391.
36. Llovet JM, Vilana R, Bru C, et al.: Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001, 33:1124-1129.
37. Livraghi T, Goldberg SN, Lazzaroni S, et al.: Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology 1999, 210:655-661.
38. Livraghi T, Goldberg SN, Lazzaroni S: Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000, 214:761-768.
39. Lencioni R, Cioni D, Crocetti L, et al.: Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005, 234:961-967.
40. Shetty SK, Rosen MP, Raptopoulos V, et al.: Cost-effectiveness of percutaneous radiofrequency ablation for malignant hepatic neoplasms. J Vasc Interv Radiol 2001, 12:823-833.
41. Lu DSK, Yu NC, Raman SS, et al.: Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005, 41:1130-1137.
42. Zhou XD, Tang ZY: Cryotherapy for primary liver cancer. Semin Surg Oncol 1998, 14:171-174.
43. Pearson AS, Izzo F, Fleming RY, et al.: Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999, 178:592-599.
44. Di Stasi M, Buscarini L, Livraghi T, et al.: Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complications rates. Scand J Gastroenterol 1997, 32:1168-1173.
45. Meloni F, Lazzaroni S, Livraghi T: Percutaneous ethanol injection: single session treatment. Eur J Ultrasound 2001, 13:107-115.
46. De Sanctis JT, Goldberg SN, Mueller PR: Percutaneous treatment of hepatic neoplasms: a review of current techniques. Cardiovac Intervent Radiol 1998, 21:273-296.
47. Di Stasi M, Buscarini L, Livraghi T, et al.: Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol 1997, 32:1168-1173.
48. Omata M, Tateishi R, Yoshida H, et al.: Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004, 127:S159-S166.
49. Giorgio A, Tarantino L, de Stefano G, et al.: Ultrasound-guided percutaneous ethanol injection under general anesthesia for the treatment of hepatocellular carcinoma on cirrhosis: long-term results in 268 patients. Eur J Ultrasound 2000, 12:145-154.
50. Lencioni RA, Allgaier HP, Cioni D, et al.: Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003, 228:235-240.
51. Liang HL, Yang CF, Pan HB, et al.: Small hepatocellular carcinoma: safety and efficacy of single high-dose percutaneous acetic acid injection for treatment. Radiology 2000, 214:769-774.
52. Huo TI, Huang YH, Wu JC: Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand J Gastroenterol 2003, 38:770-778.
53. Llovet JM, Real MI, Montanya X, et al.: Arterial embolization, chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002, 359:1734-1739.
54. Lo CM, Ngan H, Tso WK, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
55. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
56. Kurokohchi K, Watanabe S, Masaki T, et al.: Combined use of percutaneous ethanol injection and radiofrequency ablation for the effective treatment of hepatocellular carcinoma. In J Oncol 2002, 21:841-846.
57. Xu KC, Niu LZ, He WB, et al.: Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma. World J Gastroenterol 2003, 9:2686-2689.
58. Kitamoto M, Imagawa M, Yama H: Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without chemoembolization. AJR Am J Roentgenol 2003, 181:997-1003.
59. Marrero JA, Lok SF: New markers for hepatocellular carcinoma. Gastroenterology 2004, 127:S113-S119.
60. Mohr L, Yeung A, Aloman C, et al.: Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology 2004, 127:S225-S231.